Cited by 21Parkinson's Disease Mechanisms and TreatmentsSleep and related disordersSleep and Wakefulness Research

Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson’s disease patients: An ambulatory polysomnographic study

Placidi, F., Izzi, F., Romigi, A., Stanzione, P., Marciani, M. G., Brusa, L., Sperli, F., Galati, S. +2 more·2008·Journal of Neurology

Abstract

Objective To investigate the sleep-wake cycle and the effects of cabergoline monotherapy in a homogenous group of de novo Parkinson's Disease (PD) patients without confounding comorbid factors.Design and participants Twelve de novo patients affected by idiopathic PD underwent two ambulatory polysomnographic (APSG)monitoring sessions. The first was performed at baseline, and the second recording one-month after stable treatment with cabergoline monotherapy. Subjective daytime sleepiness was evaluated by means of the Epworth Sleepiness Scale.Data obtained in PD patients at baseline were compared with those obtained in 12 age- and sex-matched healthy subjects.Results Diurnal sleep parameters did not show significant differences between controls and PD patients at baseline. In PD patients, no significant changes in diurnal sleep were observed between baseline and cabergoline treatment. Regarding nocturnal sleep, patients at baseline showed a significantly lower sleep efficiency and a significantly higher Wakefulness After Sleep Onset than controls. With respect to baseline, a significant increase in REM latency and a significant reduction in REM sleep were observed during cabergoline treatment.Conclusions In the early stage of PD, the neurodegenerative process does not seem to be directly responsible for daytime somnolence, but it may be directly involved in the alteration of nocturnal sleep. Cabergoline monotherapy does not affect daytime sleep propensity and, despite clinical improvement, it may have negative effects on REM sleep.

Integrity signals

Registry

Crossref · 10.1007/s00415-008-0836-4

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Reduced amplitude of the rest-activity cycle is present in both de novo and more advanced Parkinson's disease patients, and appears to be independent of the intake of dopaminergic medications.

    “This reduced amplitude of the rest-activity cycle is present in both de novo and more advanced patients, and appears to be independent of the intake of dopaminergic medications (Piccini et al., 1991, Placidi et al., 2008, van Hilten et al., 1994, van Hilten et al., 1993, van Hilten et al., 1993).”

    From Circadian dysregulation in Parkinson's disease (2017) · cites this paper as Placidi et al., 2008

  • Studies employing actigraphy in the Parkinson's disease population revealed flattening of diurnal activity rhythms and reduced quiescence during night.

    “Studies that employed actigraphy in the PD population revealed flattening of the diurnal activity rhythms and reduced quiescence during night (Piccini et al., 1991, Placidi et al., 2008).”

    From Circadian dysregulation in Parkinson's disease (2017) · cites this paper as Placidi et al., 2008

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Placidi, F., Izzi, F., Romigi, A., Stanzione, P., Marciani, M. G., Brusa, L., Sperli, F., Galati, S., Pasqualetti, P., & Pierantozzi, M.
Affiliations
  • University of Rome Tor Vergata (IT)
  • St. Eugenio Hospital (IT)
Corresponding author
Placidi, F.
Venue
Journal of Neurology
Published
2008-06-02
Volume
255
Issue
7
Pages
1032-1037
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W1567064397
Cited by
21
References
42
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 2 · 2012: 2
FWCI
0.21
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
Keywords
Parkinson's disease, cabergoline, monotherapy, sleep-wake cycle, daytime sleepiness, nocturnal sleep, REM sleep, REM latency, sleep efficiency, wake after sleep onset, ambulatory polysomnography, Epworth Sleepiness Scale
MeSH terms
Cabergoline, Aged, Antiparkinson Agents, Ergolines, Female, Humans, Male, Middle Aged, Outpatients, Parkinson Disease, Severity of Illness Index, Sleep, Wakefulness, Case-Control Studies, Polysomnography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review